Adjunctive Treatment With Avacopan, an Oral C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

OBJECTIVE: This study aimed to evaluate the safety of avacopan, an orally administered C5a receptor inhibitor, for the treatment of antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis in addition to standard‐of‐care (SOC) treatment with glucocorticoids with cyclophosphamide or rituximab...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:ACR Open Rheumatol
Main Authors: Merkel, Peter A., Niles, John, Jimenez, Richard, Spiera, Robert F., Rovin, Brad H., Bomback, Andrew, Pagnoux, Christian, Potarca, Antonia, Schall, Thomas J., Bekker, Pirow
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7672305/
https://ncbi.nlm.nih.gov/pubmed/33128347
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/acr2.11185
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados